Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab with bortezomib and dexamethasone in relapsed or refractory multiple myeloma
NL-OMON37444Phase 2Withdrawn
- Sponsor
- Genmab
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Genmab. Primary endpoint: Incidence of adverse events. Planned start Feb 2012; status: withdrawn.
02
Drugs
daratumumabbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON37444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37444.